Transgene Sa Ord TRGNF Stock Profile

Description: Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with, Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; and collaboration and licensing agreement with Valneva; and a strategic collaboration with NEC Corporation. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Keywords: Biotechnology Cancer Life Sciences Infectious Diseases Health Care Solid Tumors Treatment Of Cancer Vaccines Hepatitis Non Small Cell Lung Cancer Lung Cancer Hepatitis B Virotherapy Small Cell Lung Cancer Viruses Glioblastoma Blastoma Liver Cancer Treatment Of Non Small Cell Lung Cancer Stoma A Therapeutic Small Cell Merck Myer Oncolytic Virus Stomach Chronic Hepatitis B Human Papilloma Virus Experimental Cancer Treatments Transgene Sa Valneva Se Pancreas Treatment Of Liver Cancer Emergent Biosolutions Pexastimogene Devacirepvec Sillajen Therapeutic Vaccines

Home Page: www.transgene.fr

400, Boulevard Gonthier d’Andernach
Illkirch-Graffenstaden, 67405
France
Phone: 33 3 88 27 91 00

Officers

Name	Title
Mr. Hedi Ben Brahim	CEO & Director
Mr. Jean-Philippe Del	VP & CFO
Dr. Eric Quemeneur Ph.D.	Exec. VP & Chief Scientific Officer
Ms. Elisabetta Castelli	Director of Investor Relations
Mr. John Felitti J.D., LLM	VP, Gen. Counsel & Corp. Sec.
Lucie Larguier	Director of Corp. Communications & IR
Ms. Gaelle Stadtler	VP & Director of HR
Mr. Philippe Slos	Head of Preclinical Regulatory Laboratory
Dr. Maud Brandely-Talbot M.D., Ph.D.	VP of Medical Affairs & Chief Medical Officer
Mr. Steven H. Bloom R.Ph.	VP & Chief Bus. Officer

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE:	0
Trailing PE:	0
Price-to-Book MRQ:	0.0177
Price-to-Sales TTM:	10.7104
IPO Date:
Fiscal Year End:	December
Full Time Employees:	143

Transgene Sa Ord(TRGNF)